Ann: Paradigm Increases Presence at OARSI World Congress 2023, page-43

I know we already have our fish to fry in terms of trials, but listening to VK speak it makes one think that the future of OA treatment is early identification and medication to slow, stall, and hopefully prevent the onset of the disease. By disrupting the inflammatory cycle of the disease, PPS is a in a great position to be this prophylactic.

VK's work is at the vanguard of biomarker identification of disease-progression, so i'd absolutely LOVE to see the results of Zilosul treatment (versus placebo) in a cohort of those identified by her biomarker test as being at high-risk of disease progression.

We've spoken about this before, but all our attempts at total addressable market to date are based on those already diagnosed with OA/BMEL, unsatisfied with current treatments, etc. This entire market (tens of millions of people who Zilosul could certainly treat) could eventually be dwarfed by people who report to their GP with sore joints, and submit to a blood test, to find that they DO NOT have OA or BMEL - BUT, they have heightened biomarkers showing them to be at risk of developing OA and therefore could benefit from treatment to slow/prevent the vicious inflammatory cycle of the disease.

This, potentially, brings into scope everyone who submits to blood tests as part of routine 6-month or annual check-ups (like many of us do) which tell us if we have high cholesterol, low iron, or numerous other easily-identifiable markers which assist in monitoring our general health and wellbeing via bloods. Wouldn't it be great to have proof that our drug impacts disease-progression in those identified by the VK biomarker blood test, were it to be adopted by the FDA?